Despite celebrating its 25th anniversary of NYSE listing on Friday, Dr Reddy's Laboratories shares have declined for five consecutive sessions, with the stock trading at ₹1,274.9, down 1.2% as of 13:19 IST on the NSE. According to Business Standard, the stock has lost approximately 0.96% in the last one month, contrasting with the Nifty Pharma index's 1.87% gain over the same period. The benchmark NIFTY is up around 0.36% on the day, while the Sensex stands at 74,624.13, up 0.48%. The stock's PE ratio stands at 33.42 based on trailing twelve months earnings ending March 2026.
Dr Reddy's Laboratories has successfully rang the Closing Bell at the New York Stock Exchange (NYSE) to celebrate 25 years of its listing on the exchange. According to the latest reports from The Hindu BusinessLine, the company became the first pharmaceutical company in Asia, outside Japan, to be listed on the NYSE in April 2001. This milestone represents a significant achievement for the Indian pharmaceutical sector in international capital markets, with the ceremony conducted on Friday afternoon to mark the occasion.
The senior management team of Dr Reddy's attended the Closing Bell ceremony at the NYSE headquarters, with Chairman Satish Reddy leading the delegation. As per the latest SEC filing, the delegation included Erez Israeli, Chief Executive Officer, M.V. Ramana, Chief Executive Officer-Global Generics, M.V. Narasimham, Chief Financial Officer, Milan Kalawadia, Chief Executive Officer-North America, K Randhir Singh, Head Company Secretary & CSR, along with Arun M. Kumar (Independent Director), Penny Wan (Independent Director), Sridar Iyengar (former Independent Director), and other officials and invitees. The ceremony was conducted at 4:00 PM EDT (1:30 AM IST on May 30th) and was commemorated with pomp and show as companies are invited to ring the bells to mark significant milestones.
Despite the recent decline, Dr Reddy's has shown resilience over longer timeframes, jumping 2.13% in the last one year compared to a 4.38% slide in NIFTY and a 11.99% spurt in the Nifty Pharma index. According to Business Standard, the stock's volume stood at 12.03 lakh shares today, compared to the daily average of 26.7 lakh shares in the last one month. The benchmark June futures contract for the stock is quoting at ₹1,284, down 0.89% on the day, indicating continued market uncertainty despite the company's significant milestone achievement.
